Xeris Biopharma (XERS)
Markets Recorlev, Gvoke and Keveyis while advancing formulation-based drug programs.
Something off on this page? Send us feedback.
Markets a U.S.-focused specialty portfolio across Cushing's syndrome, severe hypoglycemia, and primary periodic paralysis, with Recorlev, Gvoke, and Keveyis as the current products. A single reporting segment ties commercial execution to XeriSol and XeriJect formulation technology and partner development work.
Markets a U.S.-focused specialty biopharma portfolio anchored by Recorlev for Cushing's syndrome, Gvoke for severe hypoglycemia, and Keveyis for primary periodic paralysis. The business reports as one segment across chronic endocrine and neurological diseases.
Commercial execution is centered on specialty sales and product access, with a larger sales-and-marketing footprint than research organization. XeriSol and XeriJect formulation technology support internal candidates such as XP-8121 and partner programs.
The model depends on U.S. reimbursement, FDA-regulated product claims, and outside suppliers and manufacturers. Keveyis faces generic and branded-generic dichlorphenamide competition, while Recorlev's U.S. orphan exclusivity currently extends later than Keveyis' exclusivity.
Company facts
Target rangeAs of Sep 21, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Sep 10, 2026 | Leerink Partners | Reiterate | Rating: —Target: — | Target: $16 |
| Aug 20, 2026 | Barclays | Reiterate | Rating: —Target: $9 | Target: $12 |
| Dec 8, 2025 | Barclays | Target | Target: — | Target: $9 |
| Oct 29, 2025 | Oppenheimer | Reiterate | Rating: —Target: $5 | Target: $18 |
| Nov 11, 2024 | Piper Sandler | Downgrade |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $121.7M · Total debt $289.4M · Total assets $411.9M · Shareholders' equity −$9.7M
- Revenue
- $92.1M
- Operating income
- $5.2M
- Net income
- −$31.1M
No dividends on record.
| Institutions | 60.19% | 109.74M shares | |
|---|---|---|---|
| 251 holders · as of Jun 30, 2026 | |||
| Insiders | 3.61% | 6.57M shares | |
| 13 holders · as of Sep 1, 2026 | |||
| Strategic holders | 5.49% | 10.01M shares | |
| 1 holder · as of Jan 26, 2024 | |||
| Other | 30.71% | 55.99M shares | |
| remainder | |||
182.32M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
BlackRock, Inc.Institution | 7.97% | 14.53M | as of Jun 30, 2026 |
BlackRock, Inc.Strategic | 5.49% | 10.01M | filed Jan 26, 2024 |
D. E. Shaw & Co., Inc.Institution | 4.28% | 7.80M | as of Jun 30, 2026 |
Vanguard Capital Management LLCInstitution | 4.03% | 7.34M | as of Jun 30, 2026 |
State Street CorpInstitution | 2.64% | 4.82M | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Sep 1, 2026 | Steven Pieper | officer: See Remarks | −5,000 | $8.50 |
| Sep 1, 2026 | Beth Hecht | officer: See Remarks | −16,666 | $8.49 |
| Sep 1, 2026 | Kevin McCulloch | officer: See Remarks | −15,000 | $8.49 |
| Aug 12, 2026 | Steven Pieper | officer: See Remarks | −5,000 | $8.50 |
| Aug 3, 2026 | Beth Hecht | officer: See Remarks | −16,666 | $8.01 |
- Corcept Therapeutics
Commercial Cushing franchise with Korlym and relacorilant
- Amphastar Pharmaceuticals
Baqsimi and generic glucagon challenge Gvoke rescue use
- Novo Nordisk (ADR)
Zegalogue and GlucaGen overlap with Gvoke rescue products
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Xeris Biopharma | $8.79 | −0.17% | $1.52B | — | 47.2 | 4.5 | +27.2% |
| Corcept Therapeutics | $118.31 | +4.00% | $12.30B | 270.9 | 29.6 | 14.8 | +31.7% |
| Amphastar Pharmaceuticals | $24.75 | +1.08% | $1.08B | 14.5 | 7.8 | 1.5 | +5.4% |
| Novo Nordisk (ADR) | $39.33 | −1.19% | $176.83B | 9.9 | 16.2 | 3.5 | +1.3% |
| Median | 14.5 | 16.2 | 3.5 | +5.4% |